Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study.

Autor: Motzer RJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: motzerr@mkscc.org., Choueiri TK; Dana-Farber Cancer Institute, Boston, MA, USA., Hutson T; Texas Oncology, Dallas, TX, USA., Young Rha S; Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea., Puente J; Hospital Clinico San Carlos, Madrid, Spain., Lalani AA; Juravinski Cancer Centre, McMaster University, Hamilton, Canada., Winquist E; University of Western Ontario, London, Canada., Eto M; Kyushu University, Fukuoka, Japan., Basappa NS; Cross Cancer Institute, University of Alberta, Edmonton, Canada., Tannir NM; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vaishampayan U; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA., Bjarnason GA; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Canada., Oudard S; Georges Pompidou European Hospital, University Paris Cité, Paris, France., Grünwald V; University Hospital Essen, Essen, Germany., Burgents J; Merck & Co., Inc., Rahway, NJ, USA., Xie R; Eisai Inc., Nutley, NJ, USA., McKenzie J; Eisai Inc., Nutley, NJ, USA., Powles T; Barts Cancer Institute and the Royal Free Hospital, Queen Mary University of London, London, UK.
Jazyk: angličtina
Zdroj: European urology [Eur Urol] 2024 Jul; Vol. 86 (1), pp. 4-9. Date of Electronic Publication: 2024 Apr 06.
DOI: 10.1016/j.eururo.2024.03.015
Abstrakt: In the phase 3 CLEAR trial, lenvatinib plus pembrolizumab (L + P) showed superior efficacy versus sunitinib in treatment-naïve patients with advanced renal cell carcinoma (aRCC). The combination treatment was associated with a robust objective response rate of 71%. Here we report tumor responses for patients in the L + P arm in CLEAR, with median follow-up of ∼4 yr at the final prespecified overall survival (OS) analysis. Tumor responses were assessed by independent review using Response Evaluation Criteria in Solid Tumors v1.1. Patients with a complete response (CR; n = 65), partial response (PR) with maximum tumor shrinkage ≥75% (near-CR; n = 59), or PR with maximum tumor shrinkage <75% (other PR; n = 129), were characterized in terms of their baseline characteristics. The median duration of response was 43.7 mo (95% confidence interval [CI] 39.2-not estimable) for the CR group, 30.5 mo (95% CI 22.4-not estimable) for the near-CR group, and 17.2 mo (95% CI 12.5-21.4) for the other PR group. The 36-mo OS rates were consistently high in the CR (97%), near-CR (86%), and other PR (62%) groups. Robust objective response rates were observed across International Metastatic RCC Database Consortium favorable-risk (69%, 95% CI 60-78%), intermediate-risk (73%, 95% CI 67-79%), and poor-risk (70%, 95% CI 54-85%) subgroups. The robust response to L + P supports this combination as a standard-of-care first-line treatment for patients with aRCC. PATIENT SUMMARY: The CLEAR trial enrolled patients with advanced kidney cancer who had not previously received any treatment for their cancer. Here we report results for tumor shrinkage observed in the group that received lenvatinib plus pembrolizumab combination treatment during the trial. Shrinkage of target tumors with this combination was long-lasting and was observed in patients irrespective of their disease severity. This trial is registered on ClinicalTrials.gov as NCT02811861.
(Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: